Applied Therapeutics reports Q3 EPS (13c), consensus (14c)

Reports Q3 revenue $1M, consensus $250k. “Our ongoing efforts in operational execution and regulatory progress have yielded important developments in the third quarter and beginning of the fourth quarter. We completed a meeting with the FDA to discuss a potential NDA submission for govorestat for the treatment of CMT-SORD where we commenced constructive discussions as we continue to refine our regulatory strategy. We expect to submit another meeting request with the FDA to further discuss the design of a potential Phase 3 trial. We remain dedicated to advancing the development of govorestat for CMT-SORD patients and look forward to continued partnership with the FDA,” said Les Funtleyder, interim CEO and CFO of Applied Therapeutics (APLT).